A Trial to Learn How Well REGN7508 Works for Preventing Blood Clots After a Knee Replacement in Adult Participants
2期
已完成
NCT06454630
| 适应症 | Venous Thromboembolism |
|---|
| 分期 | 2期 |
|---|
| 申办方 | Regeneron Pharmaceuticals |
|---|
| 状态 | 已完成 |
|---|
| 受试者人数 | 179 人 |
|---|
| 干预（药物） | REGN7508, Enoxaparin |
|---|
| 开始日期 | 2024年6月27日 |
|---|
| 完成日期 | 2024年11月19日 |
|---|
| 结果公布日 | 2026年3月2日 |
|---|
摘要
This study is researching an experimental drug called REGN7508 (called "study drug"). The study is focused on adults undergoing elective, unilateral (one side) total knee replacement (TKR) surgery. The aim of the study is to see how effective the study drug is at preventing venous thromboembolism (VTE) and other related diseases after unilateral total knee replacement surgery. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug * How much study drug is in the blood at different times * Whether the body makes antibodies against the study drug (which could make the drug less effective or could lead to side effects)
Percentage of Participants With Confirmed, Adjudicated Venous Thromboembolism (VTE)
Through day 12 · percentage of participants
| REGN7508 | 7.1 percentage of participants |
|---|
| Enoxaparin | 17.2 percentage of participants |
|---|
在 BENITIONS 中查看
查看 ClinicalTrials.gov 原文
全部试验
本页整理自 ClinicalTrials.gov 的公开数据，不构成医疗建议，也不构成投资建议。请务必咨询专业医师。